Huntington's drug gets 4.5-Year safety check

NCT ID NCT06254482

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is following up on a previous trial to check the long-term safety and effects of the drug votoplam in people with Huntington's disease. It will track 144 participants for an additional 54 months, with everyone now receiving the active drug. The main goals are to monitor side effects and see how the drug affects key proteins linked to the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Clayton, 3168, Australia
Novartis Investigative Site

Westmead, 2145, Australia
Novartis Investigative Site

Innsbruck, 6020, Austria
Novartis Investigative Site

Ottawa, K1Y 4E9, Canada
Novartis Investigative Site

Angers, 49100, France
Novartis Investigative Site

Marseille, 13385, France
Novartis Investigative Site

Paris, 75013, France
Novartis Investigative Site

Berlin, 10117, Germany
Novartis Investigative Site

Bochum, 44791, Germany
Novartis Investigative Site

Münster, 48149, Germany
Novartis Investigative Site

Ulm, 89081, Germany
Novartis Investigative Site

Bologna, 40139, Italy
Novartis Investigative Site

Milan, 20133, Italy
Novartis Investigative Site

San Giovanni Rotondo, 71013, Italy
Novartis Investigative Site

Leiden, 2333 ZA, Netherlands
Novartis Investigative Site

Christchurch, 8011, New Zealand
Novartis Investigative Site

Barakaldo, 48903, Spain
Novartis Investigative Site

Barcelona, 8025, Spain
Novartis Investigative Site

Burgos, 90550, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Birmingham, B15 2FG, United Kingdom
Novartis Investigative Site

Cardiff, CF14 4XW, United Kingdom
Novartis Investigative Site

London, WC1N 3BG, United Kingdom
Novartis Investigative Site

Manchester, M13 9WL, United Kingdom

Conditions

Explore the condition pages connected to this study.

HUNTINGTON DISEASE